BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
61.46
+1.55 (2.59%)
At close: Aug 6, 2026, 4:00 PM EDT
64.55
+3.09 (5.03%)
After-hours: Aug 6, 2026, 7:45 PM EDT
BioMarin Pharmaceutical Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 874.01 | 1,312 | 942.84 | 755.13 | 724.53 | 587.28 |
Short-Term Investments | - | 248.93 | 194.86 | 318.68 | 567.01 | 426.6 |
Cash & Short-Term Investments | 874.01 | 1,561 | 1,138 | 1,074 | 1,292 | 1,014 |
Cash Growth | -38.97% | 37.17% | 5.95% | -16.86% | 27.39% | -4.83% |
Accounts Receivable | 1,061 | 908.21 | 660.54 | 633.7 | 461.32 | 373.4 |
Inventory | 1,783 | 1,299 | 1,233 | 1,107 | 894.08 | 776.67 |
Other Current Assets | 254.05 | 185.78 | 201.53 | 141.39 | 104.52 | 110.44 |
Total Current Assets | 3,972 | 3,953 | 3,232 | 2,956 | 2,751 | 2,274 |
Net Property, Plant & Equipment | 989.99 | 952.51 | 1,043 | 1,066 | 1,073 | 1,035 |
Other Intangible Assets | 4,879 | 213.84 | 255.28 | 294.7 | 338.57 | 388.65 |
Goodwill | 655.75 | 196.2 | 196.2 | 196.2 | 196.2 | 196.2 |
Long-Term Investments | - | 492.24 | 521.24 | 611.14 | 333.84 | 507.79 |
Other Long-Term Assets | 1,227 | 1,786 | 1,741 | 1,717 | 1,682 | 1,602 |
Total Assets | 11,723 | 7,594 | 6,989 | 6,842 | 6,375 | 6,005 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1,006 | 759.03 | 606.99 | 683.15 | 572.96 | 498.27 |
Short-Term Debt | - | - | - | 493.88 | - | - |
Current Portion of Long-Term Debt | 658.2 | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | 15.93 | 48.23 |
Total Current Liabilities | 1,664 | 759.03 | 606.99 | 1,177 | 588.88 | 546.5 |
Long-Term Debt | 3,528 | 597.18 | 595.14 | 593.1 | 1,083 | 1,079 |
Other Long-Term Liabilities | 209.82 | 150.82 | 128.82 | 119.94 | 100.02 | 113.53 |
Total Long-Term Liabilities | 3,738 | 747.99 | 723.96 | 713.03 | 1,183 | 1,193 |
Total Liabilities | 5,402 | 1,507 | 1,331 | 1,890 | 1,772 | 1,739 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.18 |
Treasury Stock | -11.23 | -10.51 | -11.23 | -9.86 | -8.86 | -9.69 |
Additional Paid-in Capital | 6,037 | 5,957 | 5,802 | 5,612 | 5,405 | 5,192 |
Accumulated Other Comprehensive Income | -8.78 | -13.47 | 61.65 | -28.79 | -3.87 | 14.43 |
Retained Earnings | 304.5 | 154.21 | -194.7 | -621.55 | -789.2 | -930.76 |
Shareholders' Equity | 6,322 | 6,087 | 5,658 | 4,952 | 4,603 | 4,266 |
Total Liabilities & Equity | 11,723 | 7,594 | 6,989 | 6,842 | 6,375 | 6,005 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 4,186 | 597.18 | 595.14 | 1,087 | 1,083 | 1,079 |
Net Cash (Debt) | -3,312 | 963.43 | 542.57 | -13.16 | 208.52 | -65.2 |
Net Cash Growth | - | 77.57% | - | - | - | - |
Net Cash Per Share | -17.06 | 4.88 | 2.76 | -0.07 | 1.10 | -0.36 |
Book Value | 6,322 | 6,087 | 5,658 | 4,952 | 4,603 | 4,266 |
Book Value Per Share | 32.57 | 30.84 | 28.76 | 25.84 | 24.36 | 23.33 |
Tangible Book Value | 786.58 | 5,677 | 5,207 | 4,461 | 4,068 | 3,681 |
Tangible Book Value Per Share | 4.05 | 28.76 | 26.47 | 23.28 | 21.53 | 20.13 |